Severe persistent asthma responsive to off-label use of omalizumab despite high and low levels of total serum IgE.
نویسندگان
چکیده
منابع مشابه
277 Serum Soluble Trail Levels in Patients With Severe Persistent Allergic Asthma: Its Relation to Omalizumab Treatment
BACKGROUND In this study we compare the Omalizumab treatment modality in the dynamics of cell apoptosis regulating molecules in both severe persistent asthma patients who had no other any allergic disease, newly diagnosed patients with allergic asthma, and healthy volunteers. MATERIAL/METHODS Severe persistent allergic asthma patients were subjected to measurement of serum soluble TRAIL (TNF-...
متن کاملSerum free IgE guided dose reduction of omalizumab: a case report
BACKGROUND Omalizumab is a human IgG1 antibody against IgE used as a therapy for sever asthmatic patients with asthma. According to the guidelines of the Global Initiative for Asthma, omalizumab is an add-on drug at treatment step 5 that is used for severe asthma patients who are allergic to perennial allergens. The effects of omalizumab for severe asthma therapy have been validated in multiple...
متن کاملAnti igE thErApy in AllErgic AsthmA And AllErgic rhinitis
The last few decades have seen a rise in the prevalence of allergic diseases, including asthma and allergic rhinitis. The prevalence asthma is estimated to be around 300 million globally and around 35% in Europe and Australasia and 60 million people in the United States are affected by rhinitis. In India prevalence asthma is estimated to be around 2.38% and 20% to 26% people suffer from allergi...
متن کاملAnti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy
The efficacy of omalizumab has been extensively investigated in clinical trials in patients with severe persistent allergic (pre-treatment total immunoglobulin E 30–700 IU?mL) asthma including the Investigation of Omalizumab in Severe Asthma Treatment (INNOVATE) study, which enrolled patients with inadequately controlled severe persistent allergic asthma despite receiving high-dose inhaled cort...
متن کاملTreating moderate-to-severe allergic asthma with anti-IgE monoclonal antibody (omalizumab). An update.
Increased asthma severity is not only associated with enhanced recurrent hospitalisation and mortality but also with higher social costs. Most cases of asthma are atopic in nature, with the trigger for acute asthma attacks and chronic worsening of inflammation being allergens inducing an immune response through immunoglobulins of IgE class. Currently antiinflammatory treatments are effective fo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia
دوره 37 4 شماره
صفحات -
تاریخ انتشار 2011